comparemela.com
Home
Live Updates
Tarlatamab Receives Accelerated Approval for Extensive-Stage SCLC : comparemela.com
Tarlatamab Receives Accelerated Approval for Extensive-Stage SCLC
The FDA has approved tarlatamab, a novel bispecific T-cell engager, to treat patients with extensive-cell small cell lung cancer (SCLC).
Related Keywords
Jay Bradner ,
Davidp Carbone ,
Laurie Fenton Ambrose ,
National Cancer Institute ,
James Thoracic Oncology Center ,
Ohio State University Medical Center ,
Amgen ,
Ohio State University Medical ,
New England Journal ,
Boxed Warning ,
comparemela.com © 2020. All Rights Reserved.